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Research
This laboratory has demonstrated that both
cadmium and arsenite can directly malig-
nantly transform the UROtsa cell line (Sens
et al. 2004). It was also shown that the tumor
heterotransplants produced by the Cd2+- and
As3+-transformed cells had histologic features
consistent with human transitional cell carci-
noma of the bladder. The parent UROtsa cell
line was developed from a primary cell cul-
ture of human urothelium that was immor-
talized using the SV40 large T-antigen
(Petzoldt et al. 1994, 1995). The UROtsa
cells proliferate in a simple serum-containing
growth medium, retain a normal cytogenetic
profile, grow as a contact-inhibited mono-
layer, and possess an undifferentiated mor-
phology consistent with basal epithelial cells.
They are not tumorigenic as judged by their
inability to form colonies in soft agar and
tumors in nude mice. 
Our laboratory also adapted the UROtsa
cells to grow in a serum-free growth medium
(Rossi et al. 2001). Under serum-free condi-
tions, the cells exhibited enhanced differentia-
tion, as evidenced by the presence of a
stratified morphology consistent with the
structural features associated with the inter-
mediate layers of the urothelium. The cells
grown in serum-free medium retained the
properties of immortality, contact inhibition,
and nontumorigenicity. 
Total RNA isolated from the parental
UROtsa cells and their As3+- and Cd2+-trans-
formed sublines grown in serum-containing
growth medium were subjected to microarray
analysis employing the U133 Plus 2.0
Affymetric chip. One of the stronger differen-
tially expressed signals between the parental
and the As3+-transformed cells was the keratin
6a gene. Our first goal in the present study
was to confirm the differential expression of
keratin 6a in the parental and transformed
UROtsa cell lines at both the mRNA and
protein levels. The second goal was to deter-
mine the expression of the keratin 6a gene in
tumor heterotransplants derived from the
As3+- and Cd2+-transformed UROtsa cells.
The final aim was to demonstrate that the
results from this model system could poten-
tially translate to human disease by determin-
ing if keratin 6a was overexpressed in archival
specimens of human bladder cancer. 
Materials and Methods
Cell culture. Stock cultures of the parent
UROtsa cell line and the cell lines malig-
nantly transformed with either 1 μM Cd2+ or
As3+ were maintained in 75 cm2 tissue culture
flasks in either serum or serum-free growth
medium as described previously (Rossi et al.
2001; Sens et al. 2004). Briefly, the serum-
containing growth medium was Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing
5% vol/vol fetal calf serum. The serum-free
growth medium was composed of a 1:1 mix-
ture of DMEM and Ham’s F-12 supple-
mented with selenium (5 ng/mL), insulin
(5 μg/mL), transferrin (5 μg/mL), hydrocorti-
sone (36 ng/mL), triiodothyronine (4 pg/mL),
glutamine (2 mM), and epidermal growth fac-
tor (EGF; 10 ng/mL). When confluent, the
cells were subcultured at a 1:20 ratio using
trypsin–EDTA. We incubated cultures at 37°C
in a 5% CO2:95% air atmosphere and fed the
cultures fresh growth medium every 3 days.
The Cd2+- and As3+-transformed cell lines were
serially passaged 10 times in Cd2+- and
As3+-free growth medium before use in any
experimental protocols or before heterotrans-
plantation into nude mice. The parental cell
line is deﬁned by the designation UROtsa. The
cells transformed with Cd2+ or As3+ in serum-
containing growth medium are deﬁned by the
designations URO-CDSC and URO-ASSC,
respectively. The cells transformed with Cd2+
or As3+ in serum-free growth medium are
deﬁned by the designations URO-CDSF and
URO-ASSF, respectively.
Tumor heterotransplants. The production
of subcutaneous nude mouse heterotrans-
plants from the Cd2+- and As3+-transformed
UROtsa cell lines has been previously
described (Sens et al. 2004). Brieﬂy, 5 × 106
cells supended in 0.2 mL phosphate-buffered
saline were injected in the dorsal thoracic mid-
line of nude (NCr-nu/nu) mice. We injected
10 mice with each transformed isolate. In the
present study, we used the tissues taken from
these tumors to determine the expression of
keratin 6a mRNA and protein. In addition to
tumor tissue harvested for histology, we also
took samples from these specimens for the
preparation of total RNA and protein.
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BACKGROUND: Cadmium and arsenite can directly and malignantly transform the UROtsa cell line.
The tumor heterotransplants produced from these transformed cells have histologic features consis-
tent with human bladder cancer. Previous microarray analysis of total RNA from the parental and
transformed cells suggested that keratin 6a was overexpressed as a result of cell transformation. 
OBJECTIVES: Our goals were to verify overexpression of keratin 6a in Cd2+- and As3+-transformed
UROtsa cells, the corresponding tumor heterotransplants, and human bladder cancer biopsy speci-
mens and to assess what factors may be involved in keratin 6a overexpression. 
METHODS: Expression was assessed with real-time polymerase chain reaction, Western blot analysis,
and immunohistochemistry. We used the effect of addition and deletion of potential growth factors
in the cell culture growth medium to assess possible pathways used in keratin 6a overexpression.
RESULTS: Cd2+- and As3+-transformed cells grown in serum-containing growth medium, as well as
the derived tumor heterotransplants, overexpressed keratin 6a mRNA and protein compared with
UROtsa cells grown in serum-containing growth medium. Immunostaining of keratin 6a in tumor
heterotransplants showed focal staining of the tumor cells that was localized to the cytoplasm. Focal
immunostaining of keratin 6a was also found in some but not all archival patient specimens of high-
grade bladder cancer, confirming translation of the results to human bladder cancer. Studies on
growth factor deletion and addition indicated that the level of keratin 6a expression was regulated by
the presence of both insulin and epidermal growth factor (EGF). In contrast, growth factors had no
effect on the elevated levels of keratin 6a expression found in transformed UROtsa cells. 
CONCLUSIONS: Our present studies suggest that keratin 6a expression may be a biomarker for
malignant urothelial cells that possess an activated EGF and or insulin growth factor pathway.
KEY WORDS: arsenic, bladder cancer, cadmium, keratin, urothelium, UROtsa. Environ Health
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17 December 2007]Protocols for the use of animals in this study
were approved by the University of North
Dakota Committee for the Care and Use of
Animals, which is in compliance with all cur-
rent National Institutes of Health (NIH)
guidelines and regulations (NIH 2002). The
facilities for animal care are accredited by the
American Association for Accreditation of
Laboratory Animal Care (AAALAC).
Bladder specimens for the retrospective
immunohistochemical analysis of keratin 6a
expression. Tissue sections for the immuno-
histochemical analysis of keratin 6a expression
in the human bladder were obtained from
archival paraffin blocks that originated from
previously completed patient diagnostic pro-
cedures. In all cases, the type of bladder can-
cer was transitional cell carcinoma, which
represents the predominant form of bladder
cancer in humans. These archival specimens
contained no patient identifiers and use was
approved by the University of North Dakota
Internal Review Board.
Immunostaining for keratin 6a in tumor
heterotransplants and archival human
specimens. We routinely ﬁxed tissues in 10%
neutral-buffered formalin for 16–18 hr. All
tissues were transferred to 70% ethanol and
dehydrated in 100% ethanol. Dehydrated tis-
sues were cleared in xylene, infiltrated, and
embedded in parafﬁn. Serial sections were cut
at 3–5 μm for use in immunohistochemical
protocols. Prior to immunostaining, sections
were immersed in preheated Target Retrieval
Solution (catalog no. S1699; Dako, Carpinteria,
CA) and heated in a steamer for 20 min. The
sections were allowed to cool to room temper-
ature and immersed into Tris-buffered saline
with Tween-20 for 5 min. Keratin 6a was
localized using a monoclonal antibody as the
primary antibody (Cat. no. ab2393; Abcam,
Cambridge, MA). For archival human speci-
mens, the primary antibody was localized
using the Dakocytomation peroxidase conju-
gated EnVision Dual link system (Cat. no.
K4061; Dako). We used liquid diaminobenzi-
dine for visualization (Dakocytomation liquid
DAB substrate chromogen system, Cat. no.
K3466; Dako). Slides were rinsed in distilled
water, dehydrated in graded ethanol, cleared
in xylene, and coverslipped. For tumor hetero-
transplants, the primary antibody was local-
ized using the DakoCytomation ARK
(Animal Research Kit; Dako), and peroxidase
(Cat. no. K3954; Dako). This system mini-
mizes reactivity of secondary antimouse anti-
body with endogenous immunoglobulin that
may be present in the heterotransplant-gener-
ated specimen. Liquid diaminobenzidine
(DAB) was used for visualization. Slides were
rinsed in distilled water, dehydrated in graded
ethanol, cleared in xylene, and coverslipped. 
Real-time analysis of keratin 6a mRNA
expression. We assessed the measurement of
keratin 6a mRNA expression with real-time
reverse transcription polymerase chain reaction
(RT-PCR) using commercially available
primers (Cat. no. QT 01003541; QIAGEN,
Valencia, CA). Total RNA was puriﬁed from
the cells lines grown in 9.6-cm2 culture wells in
triplicate, and 1 μg was subjected to cDNA
synthesis using the iScript cDNA synthesis kit
(Cat. no. 170-8890; Bio-Rad Laboratories,
Hercules CA) in a total volume of 20 μL. Real-
time RT-PCR was performed using the SYBR
Green kit (Cat. no. 170-8890; Bio-Rad
Laboratories) with 2 μL cDNA and 0.2 μM
primers in a total volume of 20 μL in an
iCycler iQ real-time detection system (Bio-Rad
Laboratories). Ampliﬁcation was monitored by
SYBR Green ﬂuorescence. Cycling parameters
consisted of denaturation at 95°C for 15 sec,
annealing at 55°C for 45 sec, and extension at
72°C, which gave optimal ampliﬁcation efﬁ-
ciency. We determined the levels of keratin 6A
mRNA relative to the UROtsa cells grown in
serum-containing medium using serial dilu-
tions of this sample as the standard curve. The
resulting relative levels were then normalized to
the change in glyceraldehyde-3-phosphate
dehydrogenase (G3PDH) expression assessed
by the same assay using the primers, sense:
TCCTCTGACTTCAACAGCGACAC and
antisense: CACCCTGTTGCTGTAGC
CAAATTC, giving a product size of 126 base
pairs and with the cycling parameters of
annealing/extension at 62°C for 45 sec and
denaturation at 95°C for 15 sec. 
Western blot analysis of keratin 6a expres-
sion. Conﬂuent cultures were harvested in 2%
sodium dodecyl sulfate (SDS) and 50 mM
Tris–HCl, pH 6.8, followed by boiling for
10 min and DNA shearing through a 23-ga
needle. We determined protein concentration
using the bicinchoninic acid protein assay
(Pierce Chemical Co., Rockford, IL) before
100 mM dithiothreitol was added to each
sample. Total cellular protein (20 μg) was
separated on a 12.5% SDS-polyacrylamide
gel electrophoresis gel and transferred to a
hybond-P polyvinylidene difluoride mem-
brane (Cat. no. RPN2020F; Amersham
Biosciences, Piscataway, NJ). Membranes
were blocked in Tris-buffered saline (TBS)
containing 0.1% Tween-20 (TBS-T) and 5%
(wt/vol) nonfat dry milk for 1 hr at room
temperature. After blocking, the membranes
were probed with the keratin 6a primary anti-
body (1:500) (Abcam) in blocking buffer
overnight. After washing 3 times in TBS, we
incubated the membranes with the antimouse
secondary antibody (1:2000) in antibody
dilution buffer for 1 hr. The blots were visual-
ized using the Phototope-HRP Western blot
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Figure 1. Expression of keratin 6a in parental UROtsa cells, UROtsa cells transformed by As3+, and UROtsa
cells transformed by Cd2+ grown in serum-containing media. (A) Real-time RT-PCR analysis of keratin 6a
mRNA levels. Relative mRNA levels were normalized to the change in G3PDH expression as described in
“Materials and Methods” and reported as the mean ± SE. (B) Western blot analysis of keratin 6a protein
levels. Gel bands developed chemiluminescently are shown.
*Statistically signiﬁcant compared with parental UROtsa cells (n = 3 parallel cell culture samples). 
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Figure 2. Expression of keratin 6a mRNA and protein in tumor heterotransplants produced by the URO-ASSC,
URO-CDSC, URO-ASSF, and URO-CDSF cell lines. (A) Real-time RT-PCR analysis of keratin 6a mRNA levels.
Relative mRNA levels were normalized to the change in G3PDH expression as described in “Materials and
Methods” (n = 3 parallel cell culture samples, reported as mean ± SE). (B) Western blot analysis of keratin 6a
protein levels. Gel bands were developed chemiluminescently.
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Signaling Technology, Beverly, MA).
UROtsa cell culture in the presence or
absence of insulin and/or EGF. UROtsa cells
were grown to conﬂuency in 6-well plates in
DMEM media supplemented with 5% fetal
calf serum. At conﬂuence, EGF (10 ng/mL),
insulin (5 μg/mL), or insulin + EGF (5 μg/mL
and 10 ng/mL, respectively) was added to the
serum-containing medium for 16 hr, and the
cells were prepared as above for the determina-
tion of keratin 6a mRNA and protein. We
performed the corollary experiment using
serum-free growth medium where EGF,
insulin, and EGF + insulin were removed
from the medium for 16 hr. 
Statistical analysis. All cell culture experi-
ments were performed in triplicate, and the
results are expressed as the mean ± SE.
Statistical analyses were performed using
Systat software (Systat Software, Inc.,
Chicago, IL) using separate variance t-tests,
analysis of variance (ANOVA) with Tukey
post-hoc testing. Unless otherwise stated, the
level of signiﬁcance was 0.05.
Results
Expression of keratin 6a mRNA and protein
in normal and transformed UROtsa cell lines.
Our laboratory performed a preliminary
microarray analysis to screen for differences in
mRNA expression between the parental
UROtsa cells and the URO-CDSC- and
URO-ASSC-transformed UROtsa cells that
were grown in serum-containing growth
medium. We performed this analysis by com-
bining triplicate total RNA samples from each
cell line and subjecting the total RNA to analy-
sis using the U133 Plus 2.0 Affymetric array
chip (Affymetrix, Inc.). The results of such an
analysis are qualitative. This analysis suggested
that the keratin 6a gene was overexpressed in
the URO-ASSC cells. The ﬁrst goal of this pre-
sent study was to confirm the results of this
preliminary microarray analysis. We prepared
total RNA and cell lysates from conﬂuent cul-
tures of UROtsa, URO-CDSC, and URO-
ASSC cells grown in serum-containing growth
medium. We subjected the total RNA to
real-time RT-PCR analysis to determine the
expression of keratin 6a mRNA. Multiple par-
allel isolates (3–5) of each group of As3+- and
Cd2+-transformed cells were available for
analysis, and one isolate from each type of
transfomation is shown as a representative of
each group. The results of this analysis con-
ﬁrmed that keratin 6a mRNA expression was
significantly elevated in URO-ASSC cells
compared with the UROtsa parental controls
(Figure 1A). The results also showed that
keratin 6a mRNA was similarly elevated in the
CDSC cells compared with the UROtsa con-
trol cells (Figure 1A). There was no difference
in keratin 6a mRNA expression between the
transformed cell lines. The level of keratin 6a
expression was determined relative to the
expression of the G3PDH housekeeping gene
It was also demonstrated using Western blot
analysis that the keratin 6a protein (56 kDa)
was elevated in both the URO-CDSC
and URO-ASSC cells compared with the
parental UROtsa cells, with the URO-CDSC
cells exhibiting 39.4 ± 0.1-fold and the
URO-ASSC cells exhibiting 24.2 ± 0.3-fold
expression over control cells as determined by
densitometry (Figure 1B). These ﬁndings con-
ﬁrmed the preliminary microarray results for
the URO-ASSC cells and extended the prelimi-
nary ﬁndings to also include the CDSC cells.
Keratin 6a mRNA and protein in tumor
heterotransplants produced by transformed
UROtsa cell lines. We also prepared total
RNA and protein lysates from subcutaneous
tumor heterotransplants generated from the
Cd2+- and As3+-transformed isolates that were
originally generated from UROtsa cells grown
in both serum-containing and serum-free
growth medium. The results of this analysis
disclosed that all four tumor heterotransplant
groups expressed highly elevated levels of
keratin 6a mRNA, 17- to 40-fold higher than
the keratin 6a mRNA expression found in the
two cell lines analyzed above (Figure 2A). A
highly elevated level of keratin 6a protein was
also demonstrated using Western blot analysis
(Figure 2B). We used immunohistochemistry
to determine the localization of keratin 6a
expression in the cells of the tumor hetero-
transplants. This analysis showed that all four
tumor heterotransplant groups contained very
frequent proﬁles of cells that were positive for
the presence of keratin 6a (Figure 3A–D).
However, keratin 6a staining was focal, and all
four tumors showed some areas of negative-
staining tumor cells. In all cases, keratin 6a
staining was diffusely cytoplasmic with no evi-
dence of nuclear localization. Stroma within the
tumors was negative for the expression of
Somji et al.
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Figure 3. Immunohistochemical staining of keratin 6a in tumor heterotransplants produced by the
URO-ASSC, URO-CDSC, URO-ASSF, and URO-CDSF cell lines. Keratin 6a staining in a heterotransplant
resulting from the injection of URO-ASSF cells (A), URO-ASSC cells (B), URO-CDSF cells (C), and URO-CDSC
cells (D). (E ) Absence of keratin 6a staining in heterotransplants derived from the human prostate carci-
noma cell line PC-3. Scale bar, 50 µm.
AB
CD
Ekeratin 6a. All transformed isolates from each
group gave similar results with focal staining and
high levels of keratin 6a expression. As a control,
heterotransplants derived from the human
prostate carcinoma cell line PC-3 did not
exhibit any staining for keratin 6a. 
Immunohistochemical staining of keratin
6a in archival specimens of human bladder
cancer. To determine if the findings in the
UROtsa model system would translate to
human bladder cancer, we performed keratin
6a staining on a small set of archival human
bladder cancer specimens. An archival specimen
that contained within a single tissue block both
a proﬁle of a high-grade urothelial cancer and
adjacent normal (noncancerous) urothelium
showed that the high-grade tumor was
immunoreactive for keratin 6a, whereas the
normal urothelium showed no staining for
keratin 6a (Figure 4A, B). Two other specimens
of high-grade cancer, one that had invaded the
underlying muscle layer (Figure 4D) and one
that had not (Figure 4C), were also shown to
stain for keratin 6a. In all three high-grade
tumors, staining was focal and cytoplasmic,
with all the tumors showing areas that were
both positive and negative for keratin 6a. A
fourth archival specimen of a high-grade
urothelial cancer was shown to have no staining
for keratin 6a (data not shown), as was a ﬁfth
archival specimen of low-grade urothelial
cancer (Figure 4E).
Expression of keratin 6a in normal and
transformed UROtsa cell lines grown in serum-
free growth medium. To complete the analysis
of keratin 6a expression in the UROtsa cell
lines, we also determined the expression of
keratin 6a mRNA and protein for the parental
UROtsa cell line and the URO-CDSF- and
URO-ASSF-transformed cell lines that had
been grown and maintained in serum-free
medium. The results of this determination
unexpectedly showed that the parental
UROtsa cells expressed high levels of both
keratin 6a mRNA and protein compared with
cells grown in serum-containing growth
medium (Figures 1A, B, and 5A, B). The
increase in expression of keratin 6a mRNA in
the UROtsa cells grown in serum-free growth
medium was approximately 50-fold higher
than the level found for cells grown in serum-
containing medium (Figures 1A and 5A) and
approximately 140-fold in keratin 6a protein
based on the optical density of the protein bands
(Figures 1B and 5B). The expression of keratin
6a mRNA and protein was also significantly
increased for the Cd2+- and As3+-transformed
cell lines, but the increase was not as large as
that found for the parental cell line with the
levels of protein reaching only about 85-fold
over the serum-containing control cells based
on gel-band densitometry (Figure 5 B). 
Deletion and addition studies on the
respective growth formulations were used to
identify the factors in the growth medium that
might be responsible for the increased expres-
sion of keratin 6a mRNA in parental UROtsa
cells grown on serum-free growth medium.
These studies showed that the addition of EGF
(10 ng/mL) for 16 hr to confluent parental
UROtsa cells grown in serum-containing
growth medium resulted in a signiﬁcant eleva-
tion in the expression of keratin 6a mRNA
(Figure 6). We also observed significant
Keratin 6a expression in malignant urothelium
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Figure 4. Immunohistochemical staining of keratin 6a in archival specimens of human bladder cancer. (A)
Absence of keratin 6a staining in normal urothelium. (B) Staining of keratin 6A in a high-grade transitional
cell carcinoma (TCC). (C) Staining of keratin 6a in a noninvasive high-grade TCC. (D) Staining of keratin 6a
in an invasive high-grade TCC that has invaded the underlying muscle layer. (E) Absence of staining of
keratin 6a staining in a low-grade urothelial cancer. Scale bar, 100 µm.
A B
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E
Figure 5. Expression of keratin 6a in parental UROtsa (UROtsa-SF), URO-CDSF, and URO-ASSF cell lines
grown and maintained in serum-free growth medium. (A) Real-time RT-PCR analysis of keratin 6a mRNA
levels. Relative mRNA levels were normalized to the change in G3PDH expression as described in
“Materials and Methods” (n = 3 parallel cell culture samples, reported as mean ± SE). (B) Western blot
analysis of keratin 6a protein levels. Gel bands were developed chemiluminescently.
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UROtsa-SF URO-ASSF URO-CDSFincreases in keratin 6a mRNA when insulin
(5 μg/mL) or insulin + EGF (5 μg/mL +
10 ng/mL) was added to the serum-containing
growth medium for 16 hr, although the
increases were less than those noted for EGF
alone (Figure 6). The addition of these compo-
nents to the parental UROtsa cells grown in
serum-containing growth medium had no
adverse effect on the cells, as judged by light
microscopy (data not shown). The deletion of
EGF from the serum-free growth medium for
16 hr was shown to significantly reduce the
expression of keratin 6a mRNA in the parental
UROtsa cells (Figure 7). The deletion of
insulin and insulin + EGF from the serum-free
growth medium was also shown to signiﬁcantly
reduce the expression of keratin 6a mRNA in
the parental UROtsa cells (Figure 7). The
reduction of keratin 6a mRNA expression
upon the deletion of insulin and insulin + EGF
was greater than when only EGF was deleted
from the serum-free medium. The deletion
studies using the serum-free growth medium
are more difficult to interpret than those on
serum-containing medium, as the removal of
any of the two components from the serum-
free medium does have an adverse effect on the
cells. At 16 hr postremoval of the growth fac-
tors, the cells are beginning to change morphol-
ogy to a more rounded appearance. At 24 hr
postremoval, the cells are rounded and begin-
ning to detach from the culture dish. However,
at 16 hr, cellular RNA is intact as monitored by
agarose gel electrophoresis (data not shown).
The removal or addition of growth factors had
no effect on keratin 6a mRNA expression for
the Cd2+- and As3+-transformed UROtsa cells
(data not shown). 
Discussion
The first goal of this present study was to
confirm a microarray analysis that suggested
that keratin 6a might be overexpressed in
urothelial cells transformed by As3+. This goal
was achieved when it was shown that keratin
6a expression was increased in both Cd2+-
and As3+-transformed UROtsa cells when
compared with parental controls. The other
goals of the study were similarly reached
when it was shown the keratin 6a was
expressed in tumor heterotransplants gener-
ated from the Cd2+- and As3+-transformed
cells and that keratin 6a was overexpressed in
some archival patient specimens of high-grade
bladder cancer. The potential role that keratin
6a might play in the development and pro-
gression of bladder cancer is presently difﬁcult
to deﬁne because the keratin 6a gene has been
only limitedly studied. The human gene was
cloned and characterized by Takahashi and
co-workers (1995) and shown to be one of
several highly related type II keratin 6 iso-
forms. Keratin 6a has been shown to be
highly induced at the wound edge in epider-
mal keratinocytes that have been injured and
to work in concert with keratin 16 in
cytoskeletal reorganization during wound
healing (Paladini et al. 1996). The analysis of
the keratin 6a promoter has localized some of
the critical regulatory sequences (Takahashi
and Coulombe 1997), and keratin 6a knock-
out mice have been shown to have delayed
wound healing (Wojcik et al. 2000). A muta-
tion in keratin 6a has been shown to be
involved in some cases of pachyonychia con-
genita types 1 and 2 (Garcia-Rio et al. 2005;
Ward et al. 2003). Overall, keratin 6a and
keratin 16 are associated with epidermal pro-
liferation and wound repair (Safer et al. 2004;
Stoler et al. 1988). A recent report associates
keratin 6a expression with urothelial cell pro-
liferation and wound repair (Sun 2006).
Keratin 6a has been found to be overexpressed
in the overlying epidermis of patients with
dermatoﬁbromas (Stoler et al. 1989), in kera-
tinizing and nonkeratinizing squamous cell
carcinomas of the cervix (Smedts et al. 1992),
and in squamous cell carcinomas of the head
and neck (Sesterhenn et al. 2005). To our
knowledge keratin 6a has not been examined
in human bladder cancer. 
There are several possibilities as to how
keratin 6a expression might affect the develop-
ment and progression of bladder cancer. The
ﬁrst is that keratin 6a expression might be only
a biomarker of upstream events in cancer
development and progression and have no
direct influence on either of these processes.
Evidence for this hypothesis is based on the
ﬁnding that keratin 6a expression in parental
UROtsa cells is up-regulated by the presence
of EGF and insulin. Additional evidence is
provided by the observation that their Cd2+-
and As3+-transformed counterparts are consti-
tutively up-regulated for keratin 6a expression
and are unaffected by the presence or absence
of EGF and insulin in the growth medium.
This finding is in agreement with another
study that shows EGF was responsible for the
induction of keratin 6a expression during the
epidermal cells response to injury (Smiley
et al. 2006). Furthermore, keratin 16, which is
co-expressed with keratin 6a during epidermal
proliferation, has been shown to be induced
by EGF through cooperation with transcrip-
tion factors Sp1 and c-Jun (Wang and Chang
2003). Our observation that insulin directly or
indirectly through interaction with the
insulin-like growth factor-1 receptor might
also regulate keratin 6a expression to our labo-
ratory’s knowledge has not been reported pre-
viously. Finally, an antibody that recognizes
both keratins 5 and 6 has been used to iden-
tify squamous differentiation in breast carci-
nomas, and lesions so identified have been
shown to have a very high frequency of EGF
receptor expression (Bossuyt et al. 2005).
Based on these scattered reports, one can
hypothesize that keratin 6a overexpression in
bladder cancer is a biomarker for malignant
cells that have an activated growth factor path-
way. Cells with an activated EGF signaling
would be expected to have an enhanced
potential to undergo progression. This is sup-
ported indirectly by the ﬁnding that keratin 6a
expression is focal in tumor heterotransplants
and in archival patient specimens. Thus,
under this hypothesis, keratin 6a would be a
biomarker for an activated cell proliferation
pathway and need not have a direct role in
cancer development or progression. 
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Figure 6. Effect of EGF and insulin on the expres-
sion levels of keratin 6a in UROtsa parental cells
grown in serum-containing medium. +, presence.
Conﬂuent UROtsa cells were grown in serum-con-
taining media with the addition of EGF alone or
insulin alone or EGF + insulin for 16 hr. The expres-
sion of keratin 6a mRNA was determined using
real-time RT-PCR. Relative mRNA levels were nor-
malized to the change in G3PDH expression as
described in “Materials and Methods” (n = 3 paral-
lel cell culture samples, reported as mean ± SE).
*Statistically signiﬁcant compared with control cells grown
in serum-containing media. **Statistically signiﬁcant com-
pared with UROtsa cells grown in serum-containing media
with the addition of EGF. 
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Figure 7. Effect of EGF and insulin deletion on the
expression levels of keratin 6a in UROtsa cells
grown in serum-free media. –, absence. Conﬂuent
UROtsa cells were cultured in serum-free media, or
in serum-free media without EGF , or without
insulin or without EGF and insulin for 16 hr. The
RNA was extracted and analyzed by real-time
RT-PCR for the expression of the keratin 6a gene.
Relative mRNA levels were normalized to the
change in G3PDH expression as described in
“Materials and Methods” (n = 3 parallel cell cul-
ture samples, reported as mean ± SE). 
*Statistically signiﬁcant compared with control cells grown
in serum-free media. **Statistically significant compared
with UROtsa cells grown in serum-free media without EGF. 
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** **A second possibility, not exclusive of the
one above, implicates keratin 6a in the
process of urothelial cell transformation and
progression that is driven by the environmen-
tal pollutant As3+. The association between
arsenic exposure and urinary bladder cancer,
typically transitional cell carcinoma, has been
observed in the same endemic areas of the
world where populations with skin cancer
have been identified (Chiou et al. 1995;
Luster and Simeonova 2004; Smith et al.
1998; Tsuda et al. 1995). In addition to neo-
plasia, other more common manifestations of
chronic arsenic exposure include hyperkerato-
sis and hyperpigmentation of the skin
(Maloney 1996). Overall, there is substantial
literature that shows skin to be unusually sen-
sitive to both arsenic’s toxic and carcinogenic
effects. One theory of why skin is highly
responsive to arsenic exposure is that skin
localizes and stores arsenic because of arsenic’s
high keratin content and the corresponding
favorable interaction with sulfhydryl groups
(Kitchin 2001; Lingren et al. 1982). If high
keratin content is indeed a driving force for
As3+-induced epidermal keratinocyte carcino-
genesis, then one can hypothesize that over-
expression of keratin 6a in the bladder due to
arsenite exposure would favor the accumula-
tion of additional arsenic by the affected blad-
der urothelial cell. If keratin 6a was induced
early during chronic arsenic exposure, this
would drive the urothelial cell’s accumulation
of intercellular arsenic metabolites and favor
the progression of cell transformation. The
accumulation of arsenic might be further
enhanced by the co-expression of keratin 16.
The finding that Cd2+ also induced the
expression of keratin 6a also fits well within
this hypothesis, as Cd2+ would also be
expected to interact similarly with keratin.
The previous finding that tumor hetero-
transplants generated from Cd2+- and As3+-
transformed UROtsa cells had increased
squamous differentiation also correlates with
the enhanced expression of keratin 6a (Sens
et al. 2004). The association of keratin 6a and
squamous differentiation is given further sig-
niﬁcance, as there is evidence that squamous
differentiation in patients with bladder cancer
is associated with a more aggressive cancer and
a poor prognosis. Squamous differentiation
has been shown to be an unfavorable prognos-
tic feature in patients undergoing radical cys-
tectomy, possibly because of its association
with high-grade tumors (Frazier et al. 1993).
Squamous differentiation has also been
reported as predictive of a poor response in
patients undergoing radiation therapy (Akdas
and Turkeri 1991; Martin et al. 1989). In
another report, squamous differentiation was
associated with a poor response to systemic
chemotherapy (Logothetis et al. 1989). Thus,
evidence suggests that overexpression of
keratin 6a could be a biomarker for tumor
progression and that it might also participate
in the enhanced urothelial cell accumulation
of the environmental pollutant arsenic. 
Keratins form a large gene family. It is now
believed that there are as many as 37 keratin
genes expressed in epithelial cells (Schweizer
et al. 2006). The expression of these proteins
has been studied extensively in cancer because
of their use in aiding the differential diagnosis
of neoplasms. Originally used to distinguish
nonepithelial from epithelial tumors, keratin
expression assessed immunohistochemically is
now used to differentiate subclasses of epithe-
lial tumors primarily for the determination of
tumor in cases of morphologically undifferen-
tiated tumors or in the identification of the
origin of a metastatic tumor whose primary
site is unknown (Chu et al. 2002). This is
made possible because of the expression of the
keratins being relatively tissue speciﬁc, with at
least one member of the acidic low-molecular-
weight keratin (class I) being co-expressed
with at least one member of the basic, high-
molecular-weight keratin (class II). Keratin
expression is also dependent on the stage
of development and the degree of terminal
differentiation. In general, antibodies to kera-
tins 7, 20, 14, and 5/6 are the most discrimi-
natory with tumors derived from simple
epithelia often positive for keratins 7 and/or
20, whereas the tumors are negative for kera-
tins 14 and 5/6. The antibody to keratin 5/6
recognizes a common epitope in both
keratins 5 and 6, but in most situations, it is
detecting keratin 5 expression and not
keratin 6. Tumors derived from stratified
epithelia are often positive for keratins 14 and
5/6 and are negative for keratins 7 and/or 20
(Chu and Weiss 2002). Occasionally keratin
expression changes, especially when there is a
change in differentiation; some of these
exceptions include some of the higher-grade
and more malignant cancers. There are exten-
sive studies detailing the rates of positivity
among the different types of tumors, giving a
good perspective on the likelihood in a spe-
cific diagnostic situation. Breast cancer is a
good example where breast epithelia express
keratins 7, 8, 18, and 19 but not keratin 20.
The basal cells and myoepithelial layers are
positive for keratins 5/6, 14, and 17 (Moll
et al. 1983). Most breast tumors will be posi-
tive for keratin 7 but negative for kera-
tins 5/6, 17, and 20 which is very useful for
distinguishing breast adenocarcimas from
adenocarcinomas from other glandular sites
(Chu et al. 2000; Tot 1999). In poorly differ-
entiated adenocarinomas from the breast,
however, some may be positive for keratins 4,
5/6, 14, or 17, which is indicative of carcino-
mas from stratified epithelial sites. These
tumors tend to have poor prognoses (Malzahn
et al. 1998). Thus, it is not uncommon that
keratin expression changes in the develop-
ment of cancer, particularly when there is a
change in differentiation. Bladder urothelium
or transitional epithelium is a special class of
epithelia with unique properties that allow for
distention during bladder filling. It has ker-
atin expression profiles that are similar to
both simple and stratified epithelia in that
keratins 7, 8, 18, and 19 (simple epithelial
keratins) are expressed in all transitional lay-
ers, whereas basal cells express keratins 5/6,
13, and 17. Keratin 20 is expressed only in
the upper layer known as the umbrella cells
(Chu and Weiss 2002). Transitional cell car-
cinomas will most often express the stratiﬁed
epithelial keratins keratins 5/6 and 17 as well
as the simple epithelial keratins 7, 8, 19 and
20 (Achtstatter et al. 1988; Schaafsma et al.
1990). Those transitional cell carcinomas that
exhibit squamous differentiation also express
keratin 14 (Chu and Weiss 2001). Keratin 13
is more abundant in low-grade tumors than
that of high grade tumors (Moll 1998). The
expression of keratin 6a is unusual compared
with other members of this gene family in
that it is usually not expressed except during
hyperproliferation. The skin is an excellent
example where keratin 6a expression is tran-
siently induced in keratinocytes at the leading
edge of a wound. Thus, unlike other keratin
isoforms, keratin 6a could potentially be a
marker for transformation, at least for certain
cancers such as transitional cell carcinomas.
The present studies show that keratin 6a is
induced in UROtsa cells malignantly trans-
formed by Cd2+ or As3+ and that keratin 6a
overexpression also occurs in high-grade
human bladder cancer. 
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